---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-013266"
form_type: "8-K"
ticker: "NTRB"
cik: "0001676047"
company_name: "NutriBand Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:20:29.421701+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales

## Summary
- Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.
- Partnership based on shared development costs in exchange for milestone payments.
- Aversa Fentanyl combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.
- Estimated peak annual US sales potential of $80M to $200M.
- AVERSA technology protected by patents in 46 countries including US, Europe, Japan.

## SEC filing metadata
- accession: 0001213900-25-013266
- form_type: 8-K
- ticker: NTRB
- cik: 0001676047
- company_name: NutriBand Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676047/000121390025013266/0001213900-25-013266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676047/000121390025013266/ea0231002-8k_nutriband.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-013266
- JSON: https://secwatch.observer/filing/0001213900-25-013266.json
- Plain text: https://secwatch.observer/filing/0001213900-25-013266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.